Repros Therapeutics today announced that the CHMP (Committee for Medicinal Products for Human Use) has formally issued a negative opinion for the centralized marketing authorization application for enclomiphene.
Moleculin Biotech, Inc. today announced the expansion of its Science Advisory Board to include Drs. Jorge Cortes and Elihu Estey.
LivaNova today announced that the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant Study (“BELIEVE”).
Moleculin today announced it has expanded the Company’s development pipeline for the treatment of acute myeloid leukemia with an immuno-stimulating STAT3 inhibitor.
LivaNova today announced Matthew J. Dodds has joined the Company as Senior Vice President, Corporate Development. In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications.
LivaNova announced the launch and enrollment of the first patient in the study to Assess Effectiveness and Efficiency of Vagus Nerve Stimulation Therapy® as Adjunctive Therapy in Patients with Difficult to Treat Depression.
Moleculin Biotech, Inc. announced that the Ethics Committee in Poland has approved the Company’s Phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).
Repros Therapeutics Inc. today announced that it has entered into a definitive agreement under which Allergan plc will acquire Repros for a cash payment of $0.67 per share.